Antibody Drug Conjugates (ADC)

Global Antibody Drug Conjugates (ADC) Market to Reach US$23.2 Billion by 2030

The global market for Antibody Drug Conjugates (ADC) estimated at US$9.4 Billion in the year 2023, is expected to reach US$23.2 Billion by 2030, growing at a CAGR of 13.8% over the analysis period 2023-2030. Breast Cancer End-Use, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$11.0 Billion by the end of the analysis period. Growth in the Blood Cancer End-Use segment is estimated at 13.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 18.5% CAGR

The Antibody Drug Conjugates (ADC) market in the U.S. is estimated at US$2.6 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.2 Billion by the year 2030 trailing a CAGR of 18.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.3% and 12.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.0% CAGR.

Global Antibody Drug Conjugates (ADC) Market - Key Trends and Drivers Summarized

What Are Antibody Drug Conjugates and How Are They Revolutionizing Cancer Treatment?

Antibody Drug Conjugates (ADCs) are a cutting-edge class of biopharmaceuticals designed to target and treat cancer with high precision. ADCs combine the targeting ability of monoclonal antibodies with potent cytotoxic drugs, enabling them to deliver chemotherapeutic agents directly to cancer cells while minimizing damage to healthy tissues. This targeted approach has made ADCs an increasingly attractive option in oncology, especially for cancers that have proven resistant to traditional treatments. By utilizing monoclonal antibodies that bind to specific proteins on the surface of cancer cells, ADCs can deliver toxic payloads more efficiently, enhancing therapeutic outcomes while reducing systemic side effects. ADCs are used in the treatment of various cancers, including breast cancer, lymphomas, and solid tumors.

How Is the ADC Market Segmented and What Are the Key Applications?

Technologically, the market is divided into types of linkers and payloads used, which are critical components in ensuring the drug’s stability and efficacy. In terms of application, breast cancer currently dominates the ADC market, given the high success rate of treatments like Kadcyla and Enhertu. Other target indications include hematologic malignancies and solid tumors, with ongoing clinical trials aiming to expand the use of ADCs to more cancer types. End-users primarily include hospitals, oncology clinics, and cancer research institutes, where ADCs are administered as part of comprehensive cancer treatment regimens. North America leads the market due to its advanced healthcare infrastructure and high investment in oncology research, while Europe and Asia-Pacific are emerging as key regions due to increasing healthcare expenditures and cancer prevalence.

How Are Technological Innovations Impacting the ADC Market?

Technological advancements are playing a pivotal role in the growth and effectiveness of ADCs. Innovations in linker chemistry have improved the stability and precision of ADCs, enabling better drug release at the cancer site and reducing off-target toxicity. Advances in cytotoxic payloads are also enhancing the potency of ADCs, making them more effective against drug-resistant cancer cells. Moreover, ongoing research in identifying new cancer biomarkers is expanding the potential applications of ADCs beyond current use cases, allowing for the development of next-generation ADCs that target previously untreatable cancers. Regulatory agencies like the FDA are also expediting approvals for new ADC therapies, recognizing their potential to transform cancer treatment.

What Factors Are Driving the Growth in the Antibody Drug Conjugates Market?

The growth in the Antibody Drug Conjugates (ADC) market is driven by several factors, including the increasing prevalence of cancer and the demand for more targeted, effective treatments. The advancements in linker technologies and payload delivery systems have enhanced the efficacy and safety profile of ADCs, contributing to their growing adoption in oncology. Furthermore, the rise in personalized medicine, where treatments are tailored to individual patients based on genetic and molecular markers, is propelling the development of ADCs. Clinical success and the approval of leading ADC products have spurred further investment in R&D, expanding the pipeline for future ADC therapies. Additionally, growing awareness and demand for therapies with fewer side effects compared to traditional chemotherapy are further driving market growth.

 

Select Competitors (Total 52 Featured) -

• ADC Therapeutics SA
• Astellas Pharma, Inc.
• AstraZeneca Plc
• Daiichi Sankyo Co., Ltd.
• Enzo Biochem, Inc.
• F. Hoffmann-La Roche AG
• Gilead Sciences, Inc.
• GSK Plc
• ImmunoGen, Inc.
• MabPlex International

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.